One-carbon metabolism and schizophrenia: current challenges and future directions

Trends in Molecular Medicine

Volumn 15, Issue 12, 2009, Pages 562-570

  Krebs, M O ^a,b   Bellon, Alfredo ^a,b   Mainguy, Gaell ^a,b   Jay, T M ^a,b   Frieling, Helge ^a,c  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; CARBON; CYANOCOBALAMIN; DOPAMINE; FOLIC ACID; GLUTAMATE RECEPTOR; GLUTAMIC ACID; HOMOCYSTEINE; METABOTROPIC RECEPTOR AGONIST; METHIONINE; METHYL GROUP; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; S ADENOSYLMETHIONINE;

ARTICLE; BRAIN DEVELOPMENT; BRAIN MITOCHONDRION; CARBON METABOLISM; CELL METABOLISM; CYANOCOBALAMIN DEFICIENCY; DISEASE COURSE; DNA METHYLATION; ENVIRONMENTAL FACTOR; EPIGENETICS; FETUS DEVELOPMENT; FOLIC ACID DEFICIENCY; GENE EXPRESSION; HEREDITY; HUMAN; HYPOTHESIS; NERVE CELL DIFFERENTIATION; OXIDATION REDUCTION REACTION; PATHOPHYSIOLOGY; PREGNANCY; SCHIZOPHRENIA;

CARBON; DNA METHYLATION; ENVIRONMENT; EPIGENESIS, GENETIC; FOLIC ACID DEFICIENCY; GENETIC PREDISPOSITION TO DISEASE; HOMOCYSTEINE; HUMANS; METABOLIC NETWORKS AND PATHWAYS; METHIONINE; MITOCHONDRIAL DISEASES; RECEPTORS, GLUTAMATE; SCHIZOPHRENIA; TIME FACTORS;

EID: 70949085092     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2009.10.001     Document Type: Article

References (97)

1. Mueser K.T., and McGurk S.R. Schizophrenia. Lancet 363 (2004) 2063-2072
2. Gray J.A., and Roth B.L. The pipeline and future of drug development in schizophrenia. Mol. Psychiatry 12 (2007) 904-922
3. Coyle J.T. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol. Neurobiol. 26 (2006) 365-384
4. McGorry P.D., et al. Back to the future: predicting and reshaping the course of psychotic disorder. Arch. Gen. Psychiatry 65 (2008) 25-27
5. Wood S.J., et al. Medial temporal lobe glutathione concentration in first episode psychosis: a 1H-MRS investigation. Neurobiol. Dis. 33 (2009) 354-357
6. MacDonald A.W., and Schulz S.C. What we know: findings that every theory of schizophrenia should explain. Schizophr. Bull. 35 (2009) 493-508
7. Tandon R., et al. Schizophrenia, "just the facts": what we know in 2008. 2. Epidemiology and etiology. Schizophr. Res. 102 (2008) 1-18
8. Rapoport J.L., et al. The neurodevelopmental model of schizophrenia: update 2005. Mol. Psychiatry 10 (2005) 434-449
9. Mittal V.A., et al. Gene-environment interaction and covariation in schizophrenia: the role of obstetric complications. Schizophr. Bull. 34 (2008) 1083-1094
10. Picker J.D., and Coyle J.T. Do maternal folate and homocysteine levels play a role in neurodevelopmental processes that increase risk for schizophrenia?. Harv. Rev. Psychiatry 13 (2005) 197-205
11. Abdolmaleky H.M., et al. Methylomics in psychiatry: modulation of gene-environment interactions might be through DNA methylation. Am. J. Med. Gen. Part B: Neuropsychiatric Genet. 127 (2004) 51-59
12. Tsankova N., et al. Epigenetic regulation in psychiatric disorders. Nat. Rev. Neurosci. 8 (2007) 355-367
13. Mill J., et al. Epigenomic profiling reveals DNA methylation changes associated with major psychosis. Am. J. Hum. Genet. 82 (2008) 696-711
14. Harrison P.J., and Weinberger D.R. Schizophrenia genes, gene expression and neuropathology: on the matter of their convergence. Mol. Psychiatry 10 (2005) 40-68 Image 45
15. Javitt D.C. Glutamate and schizophrenia: phencyclidine, N-methyl-d-Aspartate receptors and dopamine-glutamate interactions. Int. Rev. Neurobiol. 78 (2007) 69-108
16. Ben-Shachar D., and Laifenfeld D. Mitochondria, synaptic plasticity and schizophrenia. Int. Rev. Neurobiol. 59 (2004) 273-296
17. Ben-Shachar D., and Karry R. Neuroanatomical pattern of mitochondrial complex I pathology varies between schizophrenia, bipolar disorder and major depression. PLoS ONE 3 (2008) e3676
18. Rollins B., et al. Mitochondrial variants in schizophrenia, bipolar disorder and major depressive disorder. PLoS ONE 4 (2009) e4913
19. Smythies J.R., et al. Disturbances of one-carbon metabolism in neuropsychiatric disorders: a review. Biol. Psychiatry 41 (1997) 230-233
20. Loenen W.A. S-adenosylmethionine: jack of all trades and master of everything?. Biochem. Soc. Trans. 34 (2006) 330-333
21. Cohen S.M., et al. The administration of methionine to chronic schizophrenic patients: a review of 10 studies. Biol. Psychiatry 8 (1974) 209-225
22. Tremolizzo L., et al. An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia vulnerability. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 17095-17100
23. Guidotti A., et al. Decrease in reelin and glutamic acid decarboxylase 67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch. Gen. Psychiatry 57 (2000) 1061-1069
24. Lewis D.A., et al. Cortical inhibitory neurons and schizophrenia. Nat. Rev. Neurosci. 6 (2005) 312-324
25. Ruzicka W.B., et al. Selective epigenetic alteration of layer I GABAergic neurons isolated from prefrontal cortex of schizophrenia patients using laser-assisted microdissection. Mol. Psychiatry 12 (2007) 385-397
26. Tochigi M., et al. Methylation status of the reelin promoter region in the brain of schizophrenic patients. Biol. Psychiatry 63 (2008) 530-533
27. Huang H.S., and Akbarian S. GAD1 mRNA expression and DNA methylation in prefrontal cortex of subjects with schizophrenia. PLoS ONE 2 (2007) e809
28. Shimabukuro M., et al. Global hypomethylation of peripheral leukocyte DNA in male patients with schizophrenia: a potential link between epigenetics and schizophrenia. J. Psychiatr. Res. 41 (2006) 1042-1046
29. Abdolmaleky H.M., et al. Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder. Hum. Mol. Genet. 15 (2006) 3132-3145
30. Pamplona R., and Barja G. Mitochondrial oxidative stress, aging and caloric restriction: the protein and methionine connection. Biochim. Biophys. Acta 1757 (2006) 496-508
31. Wartanowicz M., et al. Assessment of nutritional folate status and selected vitamin status of women of childbearing age. Eur. J. Clin. Nutr. 55 (2001) 743-747
32. Young S.N., and Ghadirian A.M. Folic acid and psychopathology. Prog. Neuropsychopharmacol. Biol. Psychiatry 13 (1989) 841-863
33. Haidemenos A., et al. Plasma homocysteine, folate and B12 in chronic schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 31 (2007) 1289-1296
34. Petronijevic N.D., et al. Plasma homocysteine levels in young male patients in the exacerbation and remission phase of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 32 (2008) 1921-1926
35. Muntjewerff J.W., et al. Homocysteine metabolism and B vitamins in schizophrenic patients: low plasma folate as a possible independent risk factor for schizophrenia. Psychiatry Res. 121 (2003) 1-9
36. Stahl Z., et al. Nutritional and lifestyle determinants of plasma homocysteine in schizophrenia patients. Eur. Neuropsychopharmacol. 15 (2005) 291-295
37. Neeman G., et al. Relation of plasma glycine, serine and homocysteine levels to schizophrenia symptoms and medication type. Am. J. Psychiatry 162 (2005) 1738-1740
38. Muntjewerff J.W., et al. Hyperhomocysteinemia, methylenetetrahydrofolate reductase 677TT genotype and the risk for schizophrenia: a Dutch population based case-control study. Am. J. Med. Gen. Part B: Neuropsychiatric Genet. 135 (2005) 69-72
39. Muntjewerff J.W., et al. Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta-analysis. Mol. Psychiatry 11 (2006) 143-149
40. Brown A.S., and Susser E.S. Prenatal nutritional deficiency and risk of adult schizophrenia. Schizophr. Bull. 34 (2008) 1054-1063
41. Zammit S., et al. Schizophrenia and neural tube defects: comparisons from an epidemiological perspective. Schizophr. Bull. 33 (2007) 853-858
42. Rosenquist T.H., and Finnell R.H. Genes, folate and homocysteine in embryonic development. Proc. Nutr. Soc. 60 (2001) 53-61
43. Brown A.S., et al. Elevated prenatal homocysteine levels as a risk factor for schizophrenia. Arch. Gen. Psychiatry 64 (2007) 31-39
44. Di Simone N., et al. Homocysteine induces trophoblast cell death with apoptotic features. Biol. Reprod. 69 (2003) 1129-1134
45. Burdge G.C., et al. Dietary protein restriction of pregnant rats in the F0 generation induces altered methylation of hepatic gene promoters in the adult male offspring in the F1 and F2 generations. Br. J. Nutr. 97 (2007) 435-439
46. Waterland R.A., et al. Maternal methyl supplements increase offspring DNA methylation at Axin fused. Genesis 44 (2006) 401-406
47. Yamada K., et al. Effects of common polymorphisms on the properties of recombinant human methylenetetrahydrofolate reductase. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 14853-14858
48. Reed M.C., et al. A mathematical model gives insights into nutritional and genetic aspects of folate-mediated one-carbon metabolism. J. Nutr. 136 (2006) 2653-2661
49. Allen N.C., et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat. Genet. 40 (2008) 827-834
50. Shi J., et al. Genetic associations with schizophrenia: meta-analyses of 12 candidate genes. Schizophr. Res. 104 (2008) 96-107
51. Kruman I.I., et al. Folate deficiency inhibits proliferation of adult hippocampal progenitors. Neuroreport 16 (2005) 1055-1059
52. Sun D., et al. Brain surface contraction mapped in first-episode schizophrenia: a longitudinal magnetic resonance imaging study. Mol. Psychiatry (2008)
53. Zieminska E., and Lazarewicz J.W. Excitotoxic neuronal injury in chronic homocysteine neurotoxicity studied in vitro: the role of NMDA and group I metabotropic glutamate receptors. Acta. Neurobiol. Exp. (Wars) 66 (2006) 301-309
54. Lipton S.A., et al. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 5923-5928
55. Kartvelishvily E., et al. Neuron-derived D-serine release provides a novel means to activate N-methyl-D-aspartate receptors. J. Biol. Chem. 281 (2006) 14151-14162
56. Waziri R., et al. Abnormal serine-glycine metabolism in the brains of schizophrenics. Schizophr. Res. 8 (1993) 233-243
57. Waziri R., and Baruah S. A hyperglycinergic rat model for the pathogenesis of schizophrenia: preliminary findings. Schizophr. Res. 37 (1999) 205-215
58. Tuominen H.J., et al. Glutamatergic drugs for schizophrenia. Cochrane Database Syst. Rev. (2006) CD003730
59. Lau C.G., and Zukin R.S. NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders. Nat. Rev. Neurosci. 8 (2007) 413-426
60. Hagberg H. Mitochondrial impairment in the developing brain after hypoxia-ischemia. J. Bioenerg. Biomembr. 36 (2004) 369-373
61. Uranova N., et al. Electron microscopy of oligodendroglia in severe mental illness. Brain Res. Bull. 55 (2001) 597-610
62. Kung L., and Roberts R.C. Mitochondrial pathology in human schizophrenic striatum: a postmortem ultrastructural study. Synapse 31 (1999) 67-75
63. Kolomeets N.S., and Uranova N. Ultrastructural abnormalities of astrocytes in the hippocampus in schizophrenia and duration of illness: a postortem morphometric study. World J. Biol. Psychiatry (2009) 1-11
64. Prabakaran S., et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol. Psychiatry 9 (2004) 684-697 643
65. Regenold W.T., et al. Elevated cerebrospinal fluid lactate concentrations in patients with bipolar disorder and schizophrenia: implications for the mitochondrial dysfunction hypothesis. Biol. Psychiatry 65 (2009) 489-494
66. Ben-Shachar D., et al. Dopamine toxicity involves mitochondrial complex I inhibition: implications to dopamine-related neuropsychiatric disorders. Biochem. Pharmacol. 67 (2004) 1965-1974
67. Ho P.I., et al. Folate deprivation induces neurodegeneration: roles of oxidative stress and increased homocysteine. Neurobiol. Dis. 14 (2003) 32-42
68. Tjiattas L., et al. Folate deficiency and homocysteine induce toxicity in cultured dorsal root ganglion neurons via cytosolic calcium accumulation. Aging Cell 3 (2004) 71-76
69. Lazarewicz J.W., et al. Homocysteine-evoked 45Ca release in the rabbit hippocampus is mediated by both NMDA and group I metabotropic glutamate receptors: in vivo microdialysis study. Neurochem. Res. 28 (2003) 259-269
70. Zieminska E., et al. Excitotoxic neuronal injury in acute homocysteine neurotoxicity: role of calcium and mitochondrial alterations. Neurochem. Int. 48 (2006) 491-497
71. Duan W., et al. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J. Neurochem. 80 (2002) 101-110
72. Austin R.C., et al. Homocysteine-dependent alterations in mitochondrial gene expression, function and structure. J. Biol. Chem. 273 (1998) 30808-30817
73. Martorell L., et al. New variants in the mitochondrial genomes of schizophrenic patients. Eur. J. Hum. Genet. 14 (2006) 520-528
74. Marchbanks R.M., et al. A mitochondrial DNA sequence variant associated with schizophrenia and oxidative stress. Schizophr. Res. 65 (2003) 33-38
75. Tyagi N., et al. Mitochondrial mechanism of oxidative stress and systemic hypertension in hyperhomocysteinemia. J. Cell. Biochem. 96 (2005) 665-671
76. Bamne M.N., et al. Systematic association studies of mitochondrial DNA variations in schizophrenia: focus on the ND5 gene. Schizophr. Bull. 34 (2008) 458-465
77. Weil M., et al. Folic acid rescues nitric oxide-induced neural tube closure defects. Cell Death Differ. 11 (2004) 361-363
78. Brown G.C. Nitric oxide and mitochondria. Front. Biosci. 12 (2007) 1024-1033
79. Cavelier L., et al. Decreased cytochrome c oxidase activity and lack of age-related accumulation of mitochondrial DNA deletions in the brains of schizophrenics. Genomics 29 (1995) 217-224
80. Prince J.A., et al. Putamen mitochondrial energy metabolism is highly correlated to emotional and intellectual impairment in schizophrenics. Neuropsychopharmacol. 22 (2000) 284-292
81. Akbarian S., et al. Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. Arch. Gen. Psychiatry 50 (1993) 169-177
82. Fritzen S., et al. NO synthase-positive striatal interneurons are decreased in schizophrenia. Eur. Neuropsychopharmacol. 17 (2007) 595-599
83. Bernstein H.G., et al. Nitric oxide synthase-containing neurons in the human hypothalamus: reduced number of immunoreactive cells in the paraventricular nucleus of depressive patients and schizophrenics. Neuroscience 83 (1998) 867-875
84. Baba H., et al. Expression of nNOS and soluble guanylate cyclase in schizophrenic brain. Neuroreport 15 (2004) 677-680
85. Das I., et al. Elevated endogenous nitric oxide synthase inhibitor in schizophrenic plasma might reflect abnormalities in brain nitric oxide production. Neurosci. Lett. 215 (1996) 209-211
86. Dror N., et al. State-dependent alterations in mitochondrial complex I activity in platelets: a potential peripheral marker for schizophrenia. Mol. Psychiatry 7 (2002) 995-1001
87. Steullet P., et al. Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: relevance to schizophrenia. Neuroscience 137 (2006) 807-819
88. Berk M., et al. N-acetyl cysteine as a glutathione precursor for schizophrenia - a double-blind, randomized, placebo-controlled trial. Biol. Psychiatry 64 (2008) 361-368
89. Patil S.T., et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat. Med. 13 (2007) 1102-1107
90. Jhee K.H., and Kruger W.D. The role of cystathionine beta-synthase in homocysteine metabolism. Antioxid. Redox Signal 7 (2005) 813-822
91. Do K.Q., et al. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur. J.Neurosci. 12 (2000) 3721-3728
92. Yao J.K., et al. Altered glutathione redox state in schizophrenia. Dis. Markers 22 (2006) 83-93
93. Li H.C., et al. Imbalanced free radicals and antioxidant defense systems in schizophrenia: a comparative study. J. Zhejiang Univ. Sci. B 7 (2006) 981-986
94. Gysin R., et al. Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 16621-16626
95. Pae C.U., et al. Glutathione S-transferase M1 polymorphism might contribute to schizophrenia in the Korean population. Psychiatr. Genet. 14 (2004) 147-150
96. Harada S., et al. Glutathione S-transferase M1 gene deletion might be associated with susceptibility to certain forms of schizophrenia. Biochem. Biophys. Res. Commun. 281 (2001) 267-271
97. Vitvitsky V., et al. A functional transsulfuration pathway in the brain links to glutathione homeostasis. J. Biol. Chem. 281 (2006) 35785-35793